Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Thrombocythemia, Essential 2Primary Myelofibrosis 2Polycythemia Vera 2Myeloproliferative Disorders 1

Interventions

Peripheral Blood Stem Cell Transplantation 18fludarabine phosphate 17Cyclophosphamide 17Busulfan 12Tacrolimus 11Methotrexate 8Cyclosporine 8Antilymphocyte Serum 8Whole-Body Irradiation 7Mycophenolic Acid 7Filgrastim 6peginterferon alfa-2a 5Etoposide 5Prednisone 4Decitabine 4Cytarabine 4ruxolitinib 3fludarabine 3Radiotherapy 3Methylprednisolone 3Carboplatin 3Aspirin 3tipifarnib 2sonidegib 2merphos 2liposomal amphotericin B 2givinostat hydrochloride 2givinostat 2aldesleukin 2Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Thrombocythemia, Essential × LY2784544 × Clear all
NCT01134120 2018-04-17

A Study in Myeloproliferative Disorders

Eli Lilly and Company

Phase 1 Completed
80 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT01520220 2017-04-12

Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms

Eli Lilly and Company

Phase 1 Completed
100 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡